

Bubendorf, April 20, 2023

### **Bachem Annual General Meeting 2023**

- All proposals of the Board of Directors approved.
- Dividend of CHF 0.75 per share.

Bachem Holding AG (“Bachem”, SIX: BANB) announced today that its Annual General Meeting 2023 has approved all proposals of the Board of Directors. The event was held with physical presence of the shareholders for the first time since 2019. A total of 84.22 % of the 74'981'645 eligible shares were present.

The Annual General Meeting approved a dividend of CHF 0.75 per share. The dividend will be paid on April 25, 2023. The last trading day entitling to receive the dividend is April 20, 2023. As of April 21, 2023, the shares will be traded ex-dividend.

Both the Chairman and the other members of the Board of Directors were re-elected for a further year. The existing members of the Compensation Committee were also re-elected for a further year.

The shareholders approved the annual report, the financial statements of Bachem Holding AG, the consolidated financial statements for the business year 2022, as well as the appropriation of retained earnings and reserves from capital contributions and the total amount of the annual compensation paid to the Board of Directors and to the Corporate Executive Committee.

MAZARS SA, Zurich was appointed by the Annual General Meeting as auditor of Bachem Holding AG for the business year 2023.

The Annual General Meeting also approved the proposal of the Board of Directors to amend the Articles of Association.

A detailed list of all resolutions is available at

<https://www.bachem.com/about-bachem/investors-and-media/financial-events/>.

#### **Financial calendar**

April 25, 2023	Payout date for dividend
July 27, 2023	Publication of Half-Year Report 2023
March 7, 2024	Publication of Annual Report 2023; Media and Analyst conference

### **About Bachem**

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see [www.bachem.com](http://www.bachem.com).

### **For more information:**

Bachem Holding AG  
Dr. Daniel Grotzky  
Head Group Communications  
Tel.: +41 58 595 2021

**Media:** [media@bachem.com](mailto:media@bachem.com)

**Investors:** [ir@bachem.com](mailto:ir@bachem.com)